MET and lung cancer: In summary, this report confirms that MET amplification is a bona fide driver of ROS1 TKI resistance in ROS1-rearranged lung cancer and that a combination of CNS-penetrant and selective MET and ROS1 inhibitors can induce intra- and extracranial responses.